Overview

Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2021-12-19

Target enrollment:

Participant gender:

Summary

This is a single arm Phase II study, in which 4 cycles of chemotherapy (Etoposide and Cisplatin) and durvalumab with thoracic radiotherapy (52.2Gy, 2.1Gy/Fx) start at the 3rd cycle of chemotherapy and durvalumab for limited disease-small cell lung cancer. Four weeks after completion of concurrent chemoradiation therapy, patients will receive durvalumab consolidation monotherapy every 4 weeks until progression of disease or unacceptable toxicity up to the maximum duration of 2 years since enrollment.

Phase:

Phase 2

Details

Lead Sponsor:

Samsung Medical Center

Treatments:

Antibodies, Monoclonal
Cisplatin
Durvalumab
Etoposide